Stock Analysis, Dividends, Split History

PLX / Protalix BioTherapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.52
Volume321,500.00
Market Cap ($M)75.57
Enterprise Value ($M)47.25
Book Value ($M)-49.57
Book Value / Share-0.33
Price / Book-1.52
NCAV ($M)-58.24
NCAV / Share-0.39
Price / NCAV-1.30
Share Statistics
Common Shares Outstanding 145,569,955
Percentage Of Excess Shares Outstanding 0
Common Stock Shares Outstanding 143,728,797
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)2.73
Return on Assets (ROA)-1.04
Return on Equity (ROE)8.56
Balance Sheet (mrq) ($M)
Assets51.72
Liabilities101.29
Quick Ratio2.39
Current Ratio2.86
Income Statement (mra) ($M)
Licenses Revenue0.00
Revenues Other Than Company Share In Collaboration Agreement0.00
Sales Revenue Goods Net0.00
Disposal Group Including Discontinued Operation Revenue0.00
Revenues19,242,000.00
Operating Income-36.35
Net Income-85.28
Earnings Per Share Basic And Diluted-0.65
Earnings Per Share Basic-0.65
Earnings Per Share Diluted-0.65
Cash Flow Statement (mra) ($M)
Cash From Operations-9.99
Cash from Investing-1.12
Cash from Financing-1.12
Identifiers and Descriptors
CUSIP74365A101
Central Index Key (CIK)1006281
Related CUSIPS
74365A951 74365A901

Split History

Stock splits are used by Protalix BioTherapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
PLX : Protalix BioTherapeutics Stock Analysis and Research Report

2017-10-02 - Asif

Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system, or ProCellEx. The company developed its first commercial drug product, ElelysoTM, using its ProCellEx system and The company is now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With its experience to date, The company believe ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The company is now also applying the unique properties of its ProCellEx system for the oral delivery of therapeutic proteins. On May 1, 2012, the F...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Rounds Report: Protalix And Chiesi Expanded The PRX-102 Partnership To Cover U.S. Territories

2018-07-30 seekingalpha
The overall bioscience market ended the trading session with pervasive pessimism. Nevertheless, several equities under our coverage continued to log further gains for shareholders. (0-5)

Chiesi Gains U.S. Rights to Protalix' Phase III Fabry Disease Candidate PRX-102

2018-07-24 genengnews
As the World Debates Genome Editing Regulations, the Scientific Community Continues the Push to Democratize CRISPR (0-5)

Citadel's Bet Avrobio Does Not Suit Me At The Moment

2018-06-16 seekingalpha
Morgan Stanley, Cowen, Wells Fargo and Wedbush Pacgrow will help the company sell 22,313,687 shares at $16-$18 per share. (181-10)

Protalix BioTherapeutics: What The Latest Data For OPRX-106 Foretells

2018-06-13 seekingalpha
Protalix is innovating a novel approach to enzyme replacement therapy and other protein therapeutics based on the plant cells manufacturing system. (59-2)

Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference Mr. Yossi Maimon, Chief Financial Officer, you may begin. (59-1)

CUSIP: 74365A101